Latest Coagulation Stories

Penn State University A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis -- the formation of a harmful clot in a deep vein. The gene produces an enzyme that, if inhibited via a specific drug therapy, could offer hope to patients prone to deep-vein clots, such as those that sometimes form in the legs during lengthy airplane flights or during recuperation after major...

Research adds to the growing body of evidence of neutrophils' role in dangerous blood clots BOSTON, May 6, 2013 /PRNewswire-USNewswire/ -- It takes more than platelets, thrombin and fibrin to build a deep vein thrombosis (DVT). Increasingly, researchers are recognizing that neutrophils--cells better known for their role in immune defense--play an active role in DVT formation by releasing platelet-catching nets made of chromatin, a tightly-wound mix of DNA and associated proteins....

Kcentra(TM) Is the First FDA-Approved 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in the U.S. KING OF PRUSSIA, Pa., April 30, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra(TM) (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g.,...

Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study MOUNT KISCO, New York, USA, and Tokyo, Japan, April 25, 2013 /PRNewswire/ -- Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban,...

MONTREAL, April 16, 2013 /PRNewswire/ -- The global bleeding disorders community will come together on April 17 to mark World Hemophilia Day. This event takes on a special significance as it coincides with the 50(th) anniversary of the World Federation of Hemophilia (WFH). To commemorate its 50(th) anniversary, the WFH has launched a hemophilia awareness video entitled The Journey Begins. It explores the origins of the WFH and the inspired role that Frank Schnabel played in bringing...

CSL Behring initiates first "installment" of renewed 3-year commitment to WFH to donate coagulation factor to the WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 3, 2013 /PRNewswire/ -- As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day this month. The medicine will be used in treating patients in...

A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults. For the past 50 years, people with the heartbeat irregularity, atrial fibrillation, and others at increased risk for forming...

- Transition to Direct Business Model in Key Markets Strengthens Leadership Position in Global Hemostasis Market - BEDFORD, Mass., March 25, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL), a company of the Werfen Group, today announced total worldwide sales in 2012 of EUR476.4M (612.3M USD). In its two major business segments, Hemostasis and Critical Care Diagnostics, IL achieved significant revenue growth of 12.4% and 10.1%, respectively. Additionally, based on...

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with...